A judge in the US has ruled in favour of Illumina in a dispute with the Federal Trade Commission (FTC) over its multibillion-dollar takeover of cancer diagnosis specialist Grail, which had
Amgen's pathfinder KRAS inhibitor Lumakras has been shown to be effective in KRAS-mutated non-small cell lung cancer (NSCLC) in a phase 3 trial that should serve as a confirmation study for
Kaiku Health's year-old alliance with Novartis to develop a digital patient monitoring and management (DPPM) system for patients with melanoma is being extended, according to the two partne
A phase 2 trial of Jounce Therapeutics' ICOS agonist vopratelimab has ended in failure, casting further doubt about the validity of ICOS as a target for cancer therapies.
Aktis Oncology has gone back for another bite of the cherry in its Series A round, adding another $84 million to the $72 million raised last year to help bring its radiopharmaceuticals to m
Merck & Co's negotiations with Seagen over a possible takeover have stalled because the two sides cannot agree on a price, according to Bloomberg, citing people familiar with the matter